According to the Zhitong Finance App, Luye Pharmaceutical (02186.HK) announced that the messenger ribonucleic acid (mRNA) vaccine LY01620 independently developed by the Group will soon conduct phase II clinical trials in China. The study is intended to include histologically confirmed human papillomavirus16 (HPV16) -positive high-grade cervical squamous intraepithelial lesion (HSIL) patients to further evaluate the efficacy and safety of LY01620.

According to the Zhitong Finance App, Luye Pharmaceutical (02186.HK) announced that the messenger ribonucleic acid (mRNA) vaccine LY01620, developed independently by the Group, will soon conduct phase II clinical trials in China. The study is intended to include histologically confirmed human papillomavirus16 (HPV16) -positive high-grade cervical squamous intraepithelial lesion (HSIL) patients to further evaluate the efficacy and safety of LY01620.